Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177
Antibiotic Selection00:57

Antibiotic Selection

59.3K
Overview
59.3K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

229
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
229
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

897
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
897
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

218
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
218
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

146
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
146

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EU-HTA-Why Do Words Matter?

Journal of market access & health policy·2026
Same author

Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean.

Journal of pharmaceutical policy and practice·2026
Same author

The complex price setting and reimbursement of non-industrial advanced therapy medicinal products.

Health economics review·2026
Same author

Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons.

Rheumatology and therapy·2025
Same author

Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review.

Applied health economics and health policy·2025

Related Experiment Video

Updated: Jan 14, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.4K

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and

Mario García-Díaz1,2, Jorge Mestre-Ferrándiz3, Jaime Espín4,5,6

  • 1Andalusian School of Public Health, Granada, Spain. mario.99.mgd@gmail.com.

Pharmacoeconomics - Open
|January 13, 2026
PubMed
Summary
This summary is machine-generated.

The European Commission

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

27.5K

Related Experiment Videos

Last Updated: Jan 14, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.4K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

27.5K

Area of Science:

  • Public Health
  • Health Economics
  • Pharmaceutical Policy

Background:

  • Antimicrobial resistance (AMR) poses a significant global public health threat.
  • The European Commission (EC) proposes the Transferable Exclusivity Extension Voucher (TEEV) to incentivize novel antimicrobial development.
  • TEEV involves extending data exclusivity for a selected medicine, with a requirement for declared public R&D contributions.

Purpose of the Study:

  • To analyze the operational mechanisms and estimated costs of the TEEV.
  • To evaluate the impact of R&D cost transparency requirements associated with the TEEV.
  • To assess the potential public health benefits and drawbacks of the TEEV.

Main Methods:

  • Literature review.
  • Interviews with five experts in antimicrobial resistance (AMR).
  • Theoretical and practical analysis of the TEEV mechanism and cost implications.

Main Results:

  • A well-designed TEEV can offer substantial public health benefits and investor predictability, despite delaying generic/biosimilar entry.
  • Estimated healthcare cost per voucher is €162 million, with an average Member State cost of €6 million.
  • R&D cost transparency can inform policy but risks trade secret disclosure and reduced private investment.

Conclusions:

  • The TEEV shows promise as an incentive against AMR inaction but requires further implementation and complementary policies.
  • The TEEV, as proposed, does not inherently ensure access to new antimicrobials.
  • More research is needed on the effects of R&D cost transparency in antimicrobial development.